A new 13G filing with the Securities and Exchange Commission revealed that James E. Flynn‘s Deerfield Management has acquired 1.23 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which represent 4.51% of the company’s stock. The acquisition represents a new addition to Deerfield Management’s portfolio.
Blueprint Medicines Corp (NASDAQ:BPMC) is a biopharmaceutical company that works to discover therapies to help people who suffer from genomically defined diseases induced by abnormal kinase activation. Over the past 12 months, the company’s shares have gained 65.51%. For the second quarter of 2016, the company reported collaboration revenue of $7.07 million, and a loss per share of $0.70, compared to revenue of $2.69 million and a loss per share of $0.81 for the corresponding quarter in 2015.
Out of the 749 hedge funds followed by Insider Monkey which filed 13Fs for the June quarter, 12 were bullish on Blueprint Medicines Corp (NASDAQ:BPMC) at the end of June, up by one from the end of March. Some of the largest positions in the company on June 30 were held by Richard Driehaus’ Driehaus Capital (760,303 shares), Eli Casdin’s Casdin Capital (340,000 shares), and James A. Silverman’s Opaleye Management (250,000 shares).
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 1,231,343 | 0 | 1,231,343 | 1,231,343 | 4.51% |
| Deerfield Management Company | 0 | 1,231,343 | 0 | 1,231,343 | 1,231,343 | 4.51% |
| Deerfield Partners | 0 | 539,328 | 0 | 539,328 | 539,328 | 1.98% |
| Deerfield International Master Fund | 0 | 692,015 | 0 | 692,015 | 692,015 | 2.54% |
Page 1 of 12 – SEC Filing
(Name of Issuer)
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Insider Buying at 3 Companies Amid Historically Low Insider Buying, Plus Insider...
Mott Capital Scores on Semiconductors, Calls Netflix/Comcast Deal “A...
Scout Daily Update: Apple Inc. (AAPL) Revenues Decline Again
10 Most Successful Innovative Companies in The World in 2016
Innocoll Holdings PLC (INNL) Is In For A Big Couple Of Weeks
Here Are Two Biotechs With Catalysts Next Week
